Couverture de Discover SM Podcast

Discover SM Podcast

Discover SM Podcast

De : Blueprint Medicines
Écouter gratuitement

À propos de ce contenu audio

Welcome to the Discover SM Podcast, a podcast series exploring the world of systemic mastocytosis (SM). Initiated, organised and funded by Blueprint Medicines, a Sanofi company, this series is intended for international healthcare professionals (HCPs) outside the United States and the United Kingdom.

This podcast provides expert insights and practical guidance – from improving recognition of early signs to navigating diagnostic pathways. Whether you’re looking to deepen your understanding of this rare, heterogeneous condition or learn about diagnostic hallmarks, this series offers accessible and engaging content tailored for HCPs. Tune in to stay informed and spot missing “puzzle pieces” in complex cases, helping to shorten the diagnostic journey.

To learn more about SM, visit our Discover SM website for a wealth of information and resources, from webinar videos to downloadable guides such as a symptom checklist and algorithm leaflet.

INTBP-DAXSM-25.023, 12/2025

Copyright 2025 All rights reserved. Hygiène et vie saine Maladie et pathologies physiques
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • Getting to know SM: From discovery to recognition

      Getting to know SM: From discovery to recognition
      Jan 12 2026

      Episode 1 of DISCOVER SM – a podcast series developed for international HCPs to increase awareness of systemic mastocytosis (SM). This episode provides an introduction to SM, exploring its origins, key features, and subtypes. Expert insights highlight how the understanding of SM has evolved over time, setting the foundation for recognising and diagnosing this rare disease.

      For more information on SM, visit our Discover SM website.

      References: 1. Gülen T, et al. J Intern Med. 2016;279(3):211–228. 2. Ungerstedt J, et al. Cancers (Basel). 2022;14(16):3942. 3. Valent P, et al. Cancer Res. 2017;77(6):1261–1270. 4. Rare Disease Advisor. Systemic Mastocytosis History. Available at: https://www.rarediseaseadvisor.com/hcp-resource/systemic-mastocytosis-history/. Last accessed October 2025. 5. Jensen RT. Hematol Oncol Clin North Am. 2000;14(3):579-623. 6. Theoharides TC, et al. N Engl J Med. 2015;373(2):163–172. 7. Gilreath JA, et al. Clin Pharmacol. 2019;11:77–92. 8. Pyatilova P, et al. World Allergy Organ J. 2023;16(11):100838. 9. Universitätsklinik für Innere Medizin I. Reference Centers. Available at:https://innere-med-1.meduniwien.ac.at/unsere-klinischen-abteilungen/haematologie-und-haemostaseologie/projekte/ecnm-registry-european-competence-network-mastocytosis/centers/reference-centers/. Last accessed October 2025. 10. Valent P, et al. J Allergy Clin Immunol Pract. 2022;10(8):1999–2012.e6. 11. Berezowska S, et al. Mod Pathol. 2014;27(1):19–29. 12. Valent P, et al. Hemasphere. 2021;5(11):e646. 13. Arber DA, et al. Blood. 2022;140(11):1200–1228. 14. Khoury JD, et al. Leukemia. 2022;36(7):1703–1719. 15. Pardanani A. Am J Hematol. 2023;98(7):1097–1116. 16. Veitch S, Radia DH. Diagnostics (Basel). 2023;14(1):80. 17. Levedahl KH, et al. Eur J Oncol Nurs. 2022:60:102172. 18. Triggiani M, et al. Clin Exp Allergy. 2025;55(9):784–794. 19. Jennings SV, et al. Immunol Allergy Clin North Am. 2018;38(3):505–525.

      INTBP-DAXSM-25.021, 10/2025
      Afficher plus Afficher moins
      23 min
    Aucun commentaire pour le moment